Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 20/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3184521 | 0.90 | HSD11B1 (0.50) | HSD11B1 | |
| SCHEMBL2019921 | 0.89 | HSD11B1 (0.59) | HSD11B1 | |
| SCHEMBL2021769 | 0.89 | HSD11B1 (0.61) | HSD11B1 | |
| SCHEMBL2022099 | 0.88 | HSD11B1 (0.58) | HSD11B1 | |
| SCHEMBL2027177 | 0.88 | HSD11B1 (0.60) | HSD11B1 | |
| SCHEMBL2018450 | 0.87 | HSD11B1 (0.55) | HSD11B1 | |
| SCHEMBL2022352 | 0.86 | HSD11B1 (0.62) | HSD11B1 | |
| SCHEMBL2824936 | 0.85 | HSD11B1 (0.51) | HSD11B1 | |
| SCHEMBL2824934 | 0.85 | HSD11B1 (0.51) | HSD11B1 | |
| SCHEMBL2021300 | 0.84 | HSD11B1 (0.61) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150265613-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC (US) | 2015-09-24 | — | — | US | claimed |
| US-8993632-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC. (US) | 2015-03-31 | — | — | US | claimed |
| EP-2835367-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | AbbVie Inc. (US) | 2015-02-11 | — | — | EP | claimed |
| US-20130059829-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBVIE INC. | 2013-03-07 | — | — | US | claimed |
| US-20120289512-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2012-11-15 | — | — | US | claimed |
| US-8198331-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2012-06-12 | — | — | US | claimed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | claimed |
| WO-2011068927-A2 | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | claimed |
| US-20100152179-A9 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES (US) | 2010-06-17 | — | — | US | claimed |
| US-RE41135-E1 | Inhibitors of the 11-β-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2010-02-16 | — | — | US | claimed |
| US-20090176783-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | claimed |
| US-7528282-B2 | for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and conditions because of excessive glucocorticoid action; E-4-(2-methyl-2-phenoxy-propionylamino)-adamantane-1-carboxylic acid amide | ABBOTT LABORATORIES (US) | 2009-05-05 | — | — | US | claimed |
| WO-2009026422-A2 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | WO | claimed |
| US-20090054426-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | claimed |
| EP-1846362-A2 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2007-10-24 | — | — | EP | claimed |
| US-20070179186-A1 | for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and conditions because of excessive glucocorticoid action; E-4-(2-methyl-2-phenoxy-propionylamino)-adamantane-1-carboxylic acid amide | ABBVIE INC. | 2007-08-02 | — | — | US | claimed |
| US-7217838-B2 | Compounds such as E-4-{[1-(4-Chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid; fortherapy of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and diseases and conditions that are mediated by excessive glucocorticoid action | ABBOTT LABORATORIES (US) | 2007-05-15 | — | — | US | claimed |
| WO-2006074330-A2 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2006-07-13 | — | — | WO | claimed |
| US-20060149070-A1 | Compounds such as E-4-{[1-(4-Chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid, for therapy of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and diseases and conditions that are mediated by excessive glucocorticoid action | ABBVIE INC. | 2006-07-06 | — | — | US | claimed |
| US-9464072-B2 | Treatment of central nervous system disorders | ABBVIE INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150265613-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150099740-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES | 2015-04-09 | — | — | US | disclosed |
| US-8993632-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC. (US) | 2015-03-31 | — | — | US | disclosed |
| EP-2835367-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | AbbVie Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| US-8940902-B2 | Treatment of central nervous system disorders | ABBVIE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8871208-B2 | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof | ABBVIE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130059829-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBVIE INC. | 2013-03-07 | — | — | US | disclosed |
| US-20120289512-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2012-11-15 | — | — | US | disclosed |
| US-8198331-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2012-06-12 | — | — | US | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2011068927-A2 | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20100152179-A9 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES (US) | 2010-06-17 | — | — | US | disclosed |
| US-RE41135-E1 | Inhibitors of the 11-β-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090176783-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | disclosed |
| WO-2009073460-A2 | INHIBITION OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 FOR OCULAR NEUROPROTECTION | BAUSCH & LOMB INCORPORATED (US) | 2009-06-11 | — | — | WO | disclosed |
| US-7528282-B2 | for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and conditions because of excessive glucocorticoid action; E-4-(2-methyl-2-phenoxy-propionylamino)-adamantane-1-carboxylic acid amide | ABBOTT LABORATORIES (US) | 2009-05-05 | — | — | US | disclosed |
| WO-2009026422-A2 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054426-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | disclosed |
| EP-1846362-A2 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20070179186-A1 | for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and conditions because of excessive glucocorticoid action; E-4-(2-methyl-2-phenoxy-propionylamino)-adamantane-1-carboxylic acid amide | ABBVIE INC. | 2007-08-02 | — | — | US | disclosed |
| US-7217838-B2 | Compounds such as E-4-{[1-(4-Chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid; fortherapy of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and diseases and conditions that are mediated by excessive glucocorticoid action | ABBOTT LABORATORIES (US) | 2007-05-15 | — | — | US | disclosed |
| WO-2006074330-A2 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2006-07-13 | — | — | WO | disclosed |
| US-20060149070-A1 | Compounds such as E-4-{[1-(4-Chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid, for therapy of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and diseases and conditions that are mediated by excessive glucocorticoid action | ABBVIE INC. | 2006-07-06 | — | — | US | disclosed |
| US-20060149070-A1 | Compounds such as E-4-{[1-(4-Chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid, for therapy of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and diseases and conditions that are mediated by excessive glucocorticoid action | ABBVIE INC. | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179186-A1 | for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and conditions because of excessive glucocorticoid action; E-4-(2-methyl-2-phenoxy-propionylamino)-adamantane-1-carboxylic acid amide | HSD17B1, HSD3B1, HSD17B2 | HSD11B1 6/4885 |
| US-20100152179-A9 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CHAT, HSD17B1, ACHE | HSD11B1 5/4885 |
| US-20060149070-A1 | Compounds such as E-4-{[1-(4-Chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid, for therapy of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and diseases and conditions that are mediated by excessive glucocorticoid action | HSD17B1, HSD11B1, HSD3B1 | HSD11B1 2/4885 |
| US-20150265613-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885 |
| US-20120289512-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885 |
| US-20090054426-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CHAT, HSD17B1, ACHE | HSD11B1 5/4885 |
| US-20150099740-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CHAT, HSD17B1, ACHE | HSD11B1 5/4885 |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885 |
| US-20130059829-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CHAT, HSD17B1, ACHE | HSD11B1 5/4885 |
| US-20090176783-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.